Explore News By Topic

02/14/2018

FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer

February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  This clinical setting is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More

02/09/2018

Two new treatments have been found for prostate cancer patients who previously had no effective treatment options

Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival.  One of these “empty spaces” is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More

02/08/2018

FDA approves Abiraterone + Prednisone for Earlier Treatment of Metastatic Prostate Cancer

Back in June, we told you about the early results of the LATITUDE clinical trial, presented at the 2017 ASCO conference.   The study indicated that giving abiraterone in combination with low-dose prednisone to men who were just starting ADT delayed cancer progression by an average of 18 months.  The study... Read More

06/03/2017

2017 ASCO Meeting: Results from the LATITUDE Study

If you have just been diagnosed with metastatic prostate cancer and your doctor wants to start you on ADT (androgen deprivation therapy, such as Lupron), which shuts off the supply of testosterone and other male hormones, ask for abiraterone as well.  It could extend your life for years. But wait,... Read More